Related Experiment Video
Updated: Jun 27, 2026
12:55
Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
In Vivo CAR-Based Immune Cell Engineering: Future Applications and Challenges in Malignant Glioma.
Junya Yamaguchi1, Alejandra Bergquist1, Jianwen Lu1
1Department of Neurological Surgery, University of California, San Francisco, CA 94158, USA.
Cancers
|June 26, 2026
Summary
In vivo CAR-T cell therapy offers a promising alternative to ex vivo engineering for cancer treatment. This approach enables direct reprogramming of immune cells within the patient, potentially overcoming current limitations.
Area of Science:
- Oncology
- Immunotherapy
- Gene Therapy
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows success in blood cancers.
- Ex vivo CAR-T cell engineering has logistical and temporal limitations.
- In vivo CAR-T cell engineering is an emerging paradigm for direct patient cell reprogramming.
Purpose of the Study:
- To review the challenges and strategies for in vivo CAR-T cell engineering in malignant glioma.
- To highlight recent advancements in in vivo CAR-T cell engineering.
- To explore the potential of in vivo CAR-T cell therapy for solid tumors.
Main Methods:
- Review of current literature on CAR-T cell therapy and in vivo engineering.
- Discussion of viral engineering and nanotechnology for CAR delivery.
- Analysis of gene-editing components like Cas9 for in vivo modifications.
Main Results:
- In vivo CAR-T cell engineering advances offer off-the-shelf autologous immune therapy.
- Viral and nanotech platforms facilitate CAR and gene-editing component delivery.
- Early clinical trials show promise in hematologic malignancies, with solid tumor trials ongoing.
Conclusions:
- In vivo CAR-T cell therapy holds potential to overcome ex vivo limitations.
- Malignant glioma presents unique challenges for in vivo CAR-T cell application.
- Further research is needed to explore in vivo CAR-T cell strategies for glioma.
